UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease

Childhood arthritis is a chronic disabling disease. New medications called biologic therapies are now available to treat arthritis that target key biologic molecules that cause inflammation. Biologic therapies, while very effective in treating arthritis in children, may have serious side effects including infections and potentially cancers, and are very expensive and doctors don't know, which one to choose for which child. The investigators will develop tests that enable them to learn about the biology of each child's arthritis and be able to predict when and which biologic therapy to start and when to stop.

NCT Number	NCT06560606
Lead Sponsor	The Hospital for Sick Children Collaborators: Canadian Institutes of Health Research (CIHR), Genome Canada, Genome Alberta, The Arthritis Society, Canada, ReumaNederland, ZonMw: The Netherlands Organisation for Health Research and Development, Alberta Children's Hospital, Ontario Genomics
Conditions	Juvenile Idiopathic Arthritis
Enrollment	4,100 participants
Start Date	2018-08-24
Primary Completion	2025-03-30 (estimated)
Study Completion	2027-03-30 (estimated)
Updated on ClinicalTrials.gov	2024-08-19